Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Importance of post-approval real-word evidence.
James S. James S. Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):10-11. doi: 10.1093/ehjcvp/pvx035. Eur Heart J Cardiovasc Pharmacother. 2018. PMID: 29240879 No abstract available.
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. James S, et al. Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003. Am Heart J. 2009. PMID: 19332184 Clinical Trial.
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L; PLATO Study Group. James S, et al. Eur Heart J. 2010 Dec;31(24):3006-16. doi: 10.1093/eurheartj/ehq325. Epub 2010 Aug 29. Eur Heart J. 2010. PMID: 20802246 Free PMC article. Clinical Trial.
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh R, Bode C, Gibson CM. Povsic TJ, et al. Among authors: james s. Am Heart J. 2016 Apr;174:120-8. doi: 10.1016/j.ahj.2016.01.004. Epub 2016 Jan 18. Am Heart J. 2016. PMID: 26995378 Free article. Clinical Trial.
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
Mohammad MA, Andell P, Koul S, James S, Scherstén F, Götberg M, Erlinge D. Mohammad MA, et al. Among authors: james s. Platelets. 2017 Jun;28(4):414-416. doi: 10.1080/09537104.2016.1246714. Epub 2016 Nov 25. Platelets. 2017. PMID: 27885888
Caffeine and incidence of dyspnea in patients treated with ticagrelor.
Lindholm D, James S, Andersson J, Braun OÖ, Heller S, Henriksson P, Lauermann J, Öhagen P, Varenhorst C. Lindholm D, et al. Among authors: james s. Am Heart J. 2018 Jun;200:141-143. doi: 10.1016/j.ahj.2018.02.011. Epub 2018 Feb 16. Am Heart J. 2018. PMID: 29898843 Clinical Trial. No abstract available.
3,502 results